CTL-MAT offers reliable, quantitative, nonanimal-based pyrogen testing solutions using the Monocyte Activation Test.
Our products and services permit Ph. Eur. 2.6.30-compliant, robust and accurate detection of pyrogenic contaminants in parenteral drugs, biopharmaceuticals, cosmetics and solid medical devices.
CTL-MAT can support its customers with all their MAT related needs.
CTL-MAT, LLC was founded by Drs. Shabnam Solati and Dr. Prof. Paul Lehmann.
Drs Solati serves as CEO. She has over 14 years of Monocyte Activation Test experience with both the scientific and regulatory aspects of the technology.
Dr Lehmann is the CSO of CTL-MAT and is also the founder and CEO of Cellular Technology Limited.
Cellular Technology Limited has been the pioneer and industry leader in the development, use, and manufacturing of standardized tools for cellular immune assays. CTL’s founding scientists were the first to introduce protocols for functionality loss free cryopreservation of PBMC (patent). For over 20 years, CTL has been a leading provider of cryopreserved PBMC and cytokine detection kits.
CTL-MAT, combines CTL’s background in immune monitoring with Drs. Solati’s MAT specific expertise to support the global adaption of the Monocyte Activation Test.
CTL-MAT offers products and services for the complete integration of the Monocyte Activation Test. The MAT permits European Pharmacopoeia 2.6.30 compliant, robust and accurate detection of pyrogenic contaminants of parenteral drugs, biopharmaceuticals and solid medical devices.
CTL-MAT’s mission is to enable reliable and ethical drug releases thus reducing unnecessary animal-based testing.
GHP announces CTL winner of 2018 Technology Award: "Best Cellular Immune Assays Manufacturing Company 2018 & Leading Provider of Elispot & FluoroSpot Assays 2018"